Monoclonal antibodies: their production and clinical applications

ABSTRACT

There has been a major breakthrough in immunology and medicine in that a new technology known as 'hybridoma technology' has been developed by Kohler and Milstein in 1975. The whole concept of antiserum production is dramatically changed. This advancement in immuno-technology allows homogenous monoclonal antibody to be made in unlimited amounts and to have that antibody available indefinitely. Many of these monoclonals including human monoclonals are now commercially available in pure form. They are finding their way in a variety of applications and uses in different branches of science and medicine, particularly in clinical immunology and nuclear medicine